Four-Week vs Six-Week Antibiotic Therapy in the Management of Nonsurgically Treated Diabetic Foot Osteomyelitis: Protocol for a Multicentric, Single-Blind Randomized Clinical Trial
Vierwöchige vs. sechswöchige Antibiotikatherapie bei nicht chirurgisch behandelter diabetischer Fußosteomyelitis: Protokoll einer multizentrischen, einfach verblindeten randomisierten klinischen Studie
JMIR Research Protocols · 26.06.2026 · 15 · e93492
DOI: 10.2196/93492 ↗Auf einen Blick
Geplant ist eine randomisierte Studie zu 4 vs. 6 Wochen Antibiotikatherapie bei nicht chirurgisch behandelter diabetischer Fußosteomyelitis. Untersucht werden Remission und unerwünschte Ereignisse.
Fragestellung
Wie hoch sind Remissionsraten und unerwünschte Ereignisse unter 4 im Vergleich zu 6 Wochen Antibiotikatherapie bei nicht chirurgisch behandelter diabetischer Fußosteomyelitis?
Methode
Einfach verblindete randomisierte klinische Nichtunterlegenheitsstudie; 1:1-Randomisierung zu 4 oder 6 Wochen; Follow-up bis 6 Monate nach Absetzen der Antibiotika.
Ergebnisse
Primärer Endpunkt ist Remission 6 Monate nach Therapieende; sekundär sind unerwünschte Ereignisse. Die geplante Stichprobe umfasst 52 Teilnehmende pro Gruppe; bisher wurden 7 eingeschlossen.
Schlussfolgerung der Autor:innen
Die Studie soll hochwertige Evidenz zur optimalen Dauer der Antibiotikatherapie bei diabetischer Fußosteomyelitis liefern.
Kernaussagen
- Vergleich von 4 vs. 6 Wochen Antibiotikatherapie
- Primärendpunkt: Remission nach 6 Monaten
- Geplante Stichprobe: 52 Teilnehmende pro Gruppe
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JMIR Research Protocols, online erschienen am 26.06.2026. Verfasst von Amritava Ghosh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology & Metabolism, All India Institute of Medical Sciences Raipur, Raipur, Chhattisgarh, India. Hauptthemen laut MEDLINE: Osteomyelitis, Diabetic Foot, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetisches Fußsyndrom
Abstract (Originalsprache)
Background
Diabetic foot osteomyelitis (DFO) is a common complication and major cause of morbidity among people with diabetes mellitus. There has been growing acceptance of primarily nonsurgical (conservative) management of DFO based on antibiotics alone. However, the most appropriate duration of antibiotic therapy for DFO remains controversial. Current guidelines recommend antibiotic duration of up to 6 weeks for DFO. Although there has been growing interest in a shorter duration of antibiotic therapy, in absence of sufficient evidence, the extent to which the duration of antibiotic therapy can be shortened remains debatable. Determination of the optimal duration of antibiotic therapy would improve the outcomes of treatment of DFO while limiting side effects.
Objective
This study aims to determine the rates of remission (primary objective) and adverse events (secondary objective) associated with 4 vs 6 weeks of antibiotic therapy in nonsurgically treated DFO.
Methods
In this single-blind randomized clinical trial, eligible people with DFO who give consent will be randomized to 4 or 6 weeks of antibiotic therapy in a 1:1 ratio. Participants will be treated according to current guidelines. First, an empirical antibiotic therapy to be modified if required according to the results of bone culture will be administered. Additional supportive therapy (wound care, pressure off-loading, and professional care for control of glucose levels and other comorbidities) will be provided as indicated. Participants will be followed up until 6 months after antibiotic discontinuation. Radiographs and magnetic resonance images will be obtained at baseline, and at 6 weeks and after 6 months of discontinuation of antibiotics. Hematologic, renal, and hepatic parameters will be assessed during treatment. DFO remission—defined as a composite of sustained wound healing, absence of local or systemic signs of infection, stabilization or improvement in radiologic signs, absence of recurrence of osteomyelitis at the initial or contiguous site, and absence of requirement of amputation or bone resection—will be prospectively assessed at 6 months after end of antibiotic therapy. The investigator responsible for the outcome assessment will be blinded to participants’ group assignment. The sample size was calculated to be 52 participants in each group. The randomized clinical trial will be a noninferiority study. Outcomes will be published as intention-to-treat and per-protocol database.
Results
This study received sanction of research grant and budget allotment in March 2025. Data collection commenced in December 2025. As of February 2026, a total of 7 participants have been enrolled. The results are expected to be published by the first quarter of 2029.
Conclusions
This study is expected to generate high-quality evidence on the optimum duration of antibiotic therapy in DFO. Trial Registration Clinical Trials Registry - India CTRI/2025/02/080469; https://tinyurl.com/2aef5ex7 International Registered Report Identifier (IRRID) DERR1-10.2196/93492
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology & Metabolism, All India Institute of Medical Sciences Raipur, Raipur, Chhattisgarh, India.
- Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India.
- Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.
- All India Institute of Medical Sciences Raipur, Raipur, Chhattisgarh, India.
ORCID-Profile: Amritava Ghosh, Ashu Rastogi, Pranab Kumar Sahana, Alok Chandra Agrawal, Amit Kumar Mishra, Debajyoti Mohanty, Narendra Kuber Bodhey, Pragya Agarwala, Rachita Nanda, Mukul Bhattacharyya, Raja Ray, Archana Singh, Soumik Das, Mousumi Mukhopadhyay, Dibyendu Biswas
Zitieren
APA
Ghosh, A., Rastogi, A., Sahana, P. K., Agrawal, A. C., Mishra, A. K., Mohanty, D., Bodhey, N. K., Agarwala, P., Nanda, R., Bhattacharyya, M., Ray, R., Singh, A., Das, S., Mukhopadhyay, M., & Biswas, D. (2026). Four-Week vs Six-Week Antibiotic Therapy in the Management of Nonsurgically Treated Diabetic Foot Osteomyelitis: Protocol for a Multicentric, Single-Blind Randomized Clinical Trial. JMIR Research Protocols, 15, e93492. https://doi.org/10.2196/93492
Vancouver
Ghosh A, Rastogi A, Sahana PK, Agrawal AC, Mishra AK, Mohanty D, et al. Four-Week vs Six-Week Antibiotic Therapy in the Management of Nonsurgically Treated Diabetic Foot Osteomyelitis: Protocol for a Multicentric, Single-Blind Randomized Clinical Trial. JMIR Research Protocols. 2026;15:e93492. doi:10.2196/93492
BibTeX
@article{Ghosh2026,
author = {Ghosh, Amritava and Rastogi, Ashu and Sahana, Pranab Kumar and Agrawal, Alok Chandra and Mishra, Amit Kumar and Mohanty, Debajyoti and Bodhey, Narendra Kuber and Agarwala, Pragya and Nanda, Rachita and Bhattacharyya, Mukul and Ray, Raja and Singh, Archana and Das, Soumik and Mukhopadhyay, Mousumi and Biswas, Dibyendu},
title = {Four-Week vs Six-Week Antibiotic Therapy in the Management of Nonsurgically Treated Diabetic Foot Osteomyelitis: Protocol for a Multicentric, Single-Blind Randomized Clinical Trial},
journal = {JMIR Research Protocols},
year = {2026},
volume = {15},
pages = {e93492},
doi = {10.2196/93492}
}
EUVIMED